ATE286053T1 - Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung - Google Patents

Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung

Info

Publication number
ATE286053T1
ATE286053T1 AT98939941T AT98939941T ATE286053T1 AT E286053 T1 ATE286053 T1 AT E286053T1 AT 98939941 T AT98939941 T AT 98939941T AT 98939941 T AT98939941 T AT 98939941T AT E286053 T1 ATE286053 T1 AT E286053T1
Authority
AT
Austria
Prior art keywords
kinase
cell cycle
protein tyrosine
naphthyridinone
pct
Prior art date
Application number
AT98939941T
Other languages
English (en)
Inventor
Mark Robert Barvian
William Alexander Denny
Ellen Myra Dobrusin
James Marino Hamby
Howard Daniel Hollis Showalter
Andrew Mark Thompson
Roy Thomas Winters
Zhipei Wu
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE286053T1 publication Critical patent/ATE286053T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT98939941T 1997-08-20 1998-08-13 Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung ATE286053T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5674697P 1997-08-20 1997-08-20
PCT/US1998/016848 WO1999009030A1 (en) 1997-08-20 1998-08-13 Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation

Publications (1)

Publication Number Publication Date
ATE286053T1 true ATE286053T1 (de) 2005-01-15

Family

ID=22006345

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98939941T ATE286053T1 (de) 1997-08-20 1998-08-13 Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung

Country Status (13)

Country Link
US (1) US6150359A (de)
EP (1) EP1003745B1 (de)
JP (1) JP4965021B2 (de)
KR (1) KR20010023089A (de)
AT (1) ATE286053T1 (de)
AU (1) AU742999B2 (de)
BR (1) BR9811956B1 (de)
CA (1) CA2291222C (de)
DE (1) DE69828408T2 (de)
ES (1) ES2235353T3 (de)
NZ (1) NZ502704A (de)
WO (1) WO1999009030A1 (de)
ZA (1) ZA987491B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1801112A1 (de) * 1998-05-26 2007-06-27 Warner-Lambert Company LLC Bizyklische Pyrimidine und bizyklische 3,4-Dihydropyrimidine als Hemmer der Zellvermehrung
TR200003429T2 (tr) 1998-05-26 2001-07-23 Warner-Lambert Company Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.
WO2002060382A2 (en) * 2001-01-19 2002-08-08 Smithkline Beecham Corporation Novel compounds and uses thereof
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
AU2002233706C1 (en) 2001-02-26 2005-12-22 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US20040005567A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of cyclin-dependent kinase 4 expression
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
PL375403A1 (en) * 2002-08-06 2005-11-28 F.Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
WO2004065378A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US7449582B2 (en) * 2003-10-08 2008-11-11 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
EP1937681A1 (de) * 2005-09-14 2008-07-02 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydropyridopyrimidine als inhibitoren der c-fms-kinase
EP2094698A1 (de) * 2006-11-09 2009-09-02 F. Hoffmann-Roche AG Substituierte 6-phenylpyrido[2,3-d]pyrimidin-7-onderivate als kinaseinhibitoren und verfahren zu deren anwendung
EP2117544A4 (de) * 2006-12-19 2010-03-03 Univ Texas Biomarker zur identifizierung der reaktivierung von stat3 nach src-hemmung
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
WO2009105712A1 (en) 2008-02-22 2009-08-27 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
CN101684119B (zh) * 2008-09-27 2012-11-28 中国科学院上海药物研究所 5,8-二取代-1,6-二氮杂萘-7-羰酰胺类化合物及其制备方法、组合物和用途
US9376664B2 (en) 2010-06-14 2016-06-28 The Scripps Research Institute Reprogramming of cells to a new fate
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
IL289834B1 (en) 2012-06-13 2024-03-01 Incyte Holdings Corp Conversion of tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
JP2015532281A (ja) * 2012-09-26 2015-11-09 マンカインド コーポレイション 複数キナーゼ経路阻害剤
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
KR102513448B1 (ko) * 2016-12-16 2023-03-23 씨스톤 파마슈티컬즈 Cdk4/6 억제제
CN108264511B (zh) * 2017-01-03 2021-04-13 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和其在医药上的用途
US11174255B2 (en) 2017-05-15 2021-11-16 University Of Houston System Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3788047A2 (de) 2018-05-04 2021-03-10 Incyte Corporation Feste formen eines fgfr-inhibitors und verfahren zur herstellung davon
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
CA3120337A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
WO2020140055A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3968991A1 (de) * 2019-05-16 2022-03-23 University of Houston System Proteinkinaseinhibitoren und deren verwendung zur behandlung von krankheiten und zuständen
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022003873A (es) * 2019-10-01 2022-06-02 Goldfinch Bio Inc Inhibidores de 1,6-naftiridina sustituida de cdk5.
BR112022007163A2 (pt) 2019-10-14 2022-08-23 Incyte Corp Heterociclos bicíclicos como inibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
AR122928A1 (es) * 2020-07-10 2022-10-19 Goldfinch Bio Inc 1,6-naftiridinas sustituidas inhibidoras de cdk5
WO2022236319A1 (en) * 2021-05-07 2022-11-10 Enliven Therapeutics, Inc. Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinases
EP4352059A1 (de) 2021-06-09 2024-04-17 Incyte Corporation Tricyclische heterocyclen als fgfr-inhibitoren

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) * 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
US3639401A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 6-aryl-2 7-bis((trialkylsilyl)amino)pyrido (2 3-d)pyrimidine compounds
US4271164A (en) * 1979-04-16 1981-06-02 Warner-Lambert Company 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
CA2102780C (en) * 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
FR2706898B1 (de) * 1993-06-25 1995-09-08 Union Pharma Scient Appl
ES2146782T3 (es) * 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation

Also Published As

Publication number Publication date
CA2291222A1 (en) 1999-02-25
DE69828408D1 (de) 2005-02-03
EP1003745B1 (de) 2004-12-29
WO1999009030A1 (en) 1999-02-25
DE69828408T2 (de) 2005-12-08
KR20010023089A (ko) 2001-03-26
CA2291222C (en) 2004-03-30
AU8828998A (en) 1999-03-08
ZA987491B (en) 1999-04-21
US6150359A (en) 2000-11-21
BR9811956A (pt) 2000-08-15
NZ502704A (en) 2002-06-28
EP1003745A1 (de) 2000-05-31
BR9811956B1 (pt) 2010-06-01
ES2235353T3 (es) 2005-07-01
JP4965021B2 (ja) 2012-07-04
AU742999B2 (en) 2002-01-17
JP2001515078A (ja) 2001-09-18

Similar Documents

Publication Publication Date Title
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
ATE296799T1 (de) P38-inhibitoren
MY132496A (en) Inhibitors of p38
MY117696A (en) INHIBITORS OF p38
ATE529109T1 (de) Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
DE1019040T1 (de) Hemmung von p38 kinase aktivität durch arylharnstoff
IL136768A0 (en) INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
BR9709443B1 (pt) n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.
PL346840A1 (en) Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
MXPA03007527A (es) Enzimas que tienen actividad de alfa amilasa y metodos de uso de las mismas.
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
GB0111186D0 (en) Novel compounds
ES2177316T3 (es) Anticuerpos humanos antifacotores ix/ixa.
ATE407947T1 (de) Proteine mit il-6 inhibitorischer wirkung
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
UY26426A1 (es) Nuevos compuestos
IL149416A0 (en) Human enzymes of the metalloprotease family
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
MY127675A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
SE0202608D0 (sv) New sequences
MY129421A (en) INHIBITORS OF p38
ES2181160T3 (es) Derivados de 1,4-dihidropiridina y su utilizacion en terapia.
PT1169054E (pt) Produtos e metodos para tratar doencas relacionadas com ptp lar
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties